Announcements
- Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
- Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
- Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
- Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
- Lantheus Announces CEO Succession Plan
- Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
More ▼
Key statistics
As of last trade, Lantheus Holdings Inc (0L8:FRA) traded at 55.30, 18.69% above the 52 week low of 46.59 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.30 |
---|---|
High | 55.30 |
Low | 55.30 |
Bid | 55.98 |
Offer | 56.06 |
Previous close | 53.82 |
Average volume | 142.56 |
---|---|
Shares outstanding | 68.55m |
Free float | 66.82m |
P/E (TTM) | 13.03 |
Market cap | 4.14bn USD |
EPS (TTM) | 4.64 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:00 BST.
More ▼